MarketPulse

pharmaceutical acquisition

3 articles
The Motley FoolThe Motley Fool··Eric Volkman

Eli Lilly's $6.3B Centessa Deal Signals Aggressive Push Into Neuroscience

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.
LLYCNTAbiotechclinical trials
The Motley FoolThe Motley Fool··Seena Hassouna

Collegium's ADHD Pivot Accelerates as General Counsel Trims Stakes

Collegium's General Counsel sells modest stake as company bets $650M acquiring AZSTARYS to accelerate ADHD strategy shift, with Jornay PM showing 48% growth.
COLLrevenue growthinsider sale
BenzingaBenzinga··Globe Newswire

Eton Pharmaceuticals Bolsters Rare Disease Portfolio With HEMANGEOL Acquisition

Eton Pharmaceuticals acquires HEMANGEOL commercialization rights, the only FDA-approved infantile hemangioma treatment, expanding its portfolio to ten commercial products with 2026 earnings accretion expected.
ETONrare diseaseorphan drug